AstraZeneca’s AZD1222 Meets its Primary Endpoint in Preventing COVID-19
Shots:
- The P-III D8110C00001 study assessing AZD1222 (2 doses either 5 x1010 viral particles or saline PBO 4 wks. apart) vs PBO for the prevention of COVID-19. The interim analysis for efficacy was based on 32,449 participants aged ≥18 yrs. accruing 141 symptomatic infections in a ratio (2:1) across ~88 trial centers in and outside the US
- The results showed 79% vaccine efficacy at preventing symptomatic COVID-19, 100% efficacy at preventing severe disease and hospitalization, 80% efficacy in aged 65 yrs and over, favorable reactogenicity, and overall safety profile
- The primary analysis will be submitted for publication in a peer-reviewed journal and authorization for EUA from FDA
Click here to read full press release/ article | Ref: AstraZeneca | Image: Business Standard